HIV RNA testing in the context of nonoccupational postexposure prophylaxis
- PMID: 15243937
- DOI: 10.1086/421278
HIV RNA testing in the context of nonoccupational postexposure prophylaxis
Abstract
Background: The specificity and positive predictive value of human immunodeficiency virus (HIV) RNA assays have not been evaluated in the setting of postexposure prophylaxis (PEP).
Methods: Plasma from subjects enrolled in a nonoccupational PEP study was tested with 2 branched-chain DNA (bDNA) assays, 2 polymerase chain reaction (PCR) assays, and a transcription-mediated amplification (TMA) assay. Assay specificity and positive predictive value were determined for subjects who remained negative for HIV antibody for >or=3 months.
Results: In 329 subjects examined, the lowest specificities (90.1%-93.7%) were seen for bDNA testing performed in real time. The highest specificities were seen with batched bDNA version 3.0 (99.1%), standard PCR (99.4%), ultrasensitive PCR (100%), and TMA (99.6%) testing. Only the 2 assays with the highest specificities had positive predictive values >40%. For the bDNA assays, increasing the cutoff point at which a test is called positive (e.g., from 50 copies/mL to 500 copies/mL for version 3.0) increased both specificity and positive predictive values to 100%.
Conclusions: The positive predictive value of HIV RNA assays in individuals presenting for PEP is unacceptably low for bDNA-based testing and possibly acceptable for PCR- and TMA-based testing. Routine use of HIV RNA assays in such individuals is not recommended.
Similar articles
-
Clinical comparison of branched DNA and reverse transcriptase-PCR and nucleic acid sequence-based amplification assay for the quantitation of circulating recombinant form_BC HIV-1 RNA in plasma.AIDS. 2007 Dec;21 Suppl 8:S27-32. doi: 10.1097/01.aids.0000304693.16767.66. AIDS. 2007. PMID: 18172387
-
Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples.J Clin Virol. 2005 May;33(1):43-51. doi: 10.1016/j.jcv.2004.09.025. J Clin Virol. 2005. PMID: 15797364
-
Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens.J Clin Virol. 2005 Dec;34(4):245-52. doi: 10.1016/j.jcv.2004.12.012. J Clin Virol. 2005. PMID: 16286047
-
Diagnosis of HIV-1 infection in children younger than 18 months in the United States.Pediatrics. 2007 Dec;120(6):e1547-62. doi: 10.1542/peds.2007-2951. Pediatrics. 2007. PMID: 18055670 Review.
-
Clinical application of reverse transcription-polymerase chain reaction for HIV infection.Clin Lab Med. 1994 Jun;14(2):335-49. Clin Lab Med. 1994. PMID: 7523019 Review.
Cited by
-
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26. J Infect Dis. 2013. PMID: 23105144 Free PMC article. Clinical Trial.
-
Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.HIV Med. 2014 Aug;15(7):385-95. doi: 10.1111/hiv.12132. Epub 2014 Feb 24. HIV Med. 2014. PMID: 24580813 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous